Michael B Yaffe

List of Publications by Year in Descending Order

127 papers	11,035 citations	43 h-index	105 g-index
290 ext. papers	12,512 ext. citations	13 avg, IF	6.37 L-index

#	Paper	IF	Citations
127	MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12669	5.1	2
126	A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2022**, 40, TPS219-TPS219	2.2	0
125	Immunogenic cell stress and injury versus immunogenic cell death: implications for improving cancer treatment with immune checkpoint blockade.. *Molecular and Cellular Oncology*, **2022**, 9, 2039038	1.2	
124	An integrated pharmacological, structural, and genetic analysis of extracellular versus intracellular ROS production in neutrophils.. *Journal of Molecular Biology*, **2022**, 167533	6.5	0
123	Proteomics of Coagulopathy Following Injury Reveals Limitations of Using Laboratory Assessment to Define Trauma-Induced Coagulopathy to Predict Massive Transfusion. *Annals of Surgery Open*, **2022**, 3, e167	1	
122	The injury response to DNA damage in live tumor cells promotes antitumor immunity. *Science Signaling*, **2021**, 14, eabc4764	8.8	4
121	Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer. *Cancer Immunology Research*, **2021**, 9, 790-810	12.5	6
120	Monocyte exocytosis of mitochondrial danger-associated molecular patterns in sepsis suppresses neutrophil chemotaxis. *Journal of Trauma and Acute Care Surgery*, **2021**, 90, 46-53	3.3	7
119	A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, TPS186-TPS186	2.2	0
118	Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial. *Chest*, **2021**,	5.3	5
117	Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles. *Organic and Biomolecular Chemistry*, **2021**, 19, 7843-7854	3.9	1
116	Multi-omic analysis in injured humans: Patterns align with outcomes and treatment responses.. *Cell Reports Medicine*, **2021**, 2, 100478	18	4
115	Transite: A Computational Motif-Based Analysis Platform That Identifies RNA-Binding Proteins Modulating Changes in Gene Expression. *Cell Reports*, **2020**, 32, 108064	10.6	5
114	Coagulopathy signature precedes and predicts severity of end-organ heat stroke pathology in a mouse model. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1900-1910	15.4	11
113	Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 524-531	5.1	27
112	Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?. *Journal of Trauma and Acute Care Surgery*, **2020**, 88, 713-714	3.3	68
111	NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity. *Oncogene*, **2020**, 39, 5252-5266	7.6	7

110	Circulating Factors in Trauma Plasma Activate Specific Human Immune Cell Subsets. *Injury*, **2020**, 51, 819-829	2.5	3
109	Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1752-1755	15.4	358
108	Modern Management of Bleeding, Clotting, and Coagulopathy in Trauma Patients: What Is the Role of Viscoelastic Assays?. *Current Trauma Reports*, **2020**, 6, 69-81	0.5	5
107	Intratumoral administration of DNA-damaging chemotherapy-treated tumor cells to enhance therapeutic benefit of systemic immune checkpoint blockade in mouse cancer models.. *Journal of Clinical Oncology*, **2020**, 38, 77-77	2.2	
106	Tranexamic acid is associated with reduced complement activation in trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography. *Blood Coagulation and Fibrinolysis*, **2020**, 31, 578-582	1	3
105	Formyl Peptide Receptor-1 Blockade Prevents Receptor Regulation by Mitochondrial Danger-Associated Molecular Patterns and Preserves Neutrophil Function After Trauma. *Critical Care Medicine*, **2020**, 48, e123-e132	1.4	9
104	Monitoring and modeling of lymphocytic leukemia cell bioenergetics reveals decreased ATP synthesis during cell division. *Nature Communications*, **2020**, 11, 4983	17.4	7
103	STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study Design of the Phase IIa STARS Trial. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 984	5.1	14
102	Are redox changes a critical switch for mitotic progression?. *Molecular and Cellular Oncology*, **2020**, 7, 1832419	1.2	1
101	Redox priming promotes Aurora A activation during mitosis. *Science Signaling*, **2020**, 13,	8.8	7
100	Multiplexed Plasma Immune Mediator Signatures Can Differentiate Sepsis From NonInfective SIRS: American Surgical Association 2020 Annual Meeting Paper. *Annals of Surgery*, **2020**, 272, 604-610	7.8	3
99	BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage. *Nature Communications*, **2020**, 11, 4083	17.4	35
98	Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. *Nature Communications*, **2020**, 11, 4124	17.4	5
97	ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2060-2063	15.4	143
96	Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. *World Journal of Emergency Surgery*, **2020**, 15, 29	9.2	25
95	Inducing DNA damage through R-loops to kill cancer cells. *Molecular and Cellular Oncology*, **2020**, 8, 1848233	2.2	2
94	MAPKAP Kinase-2 Drives Expression of Angiogenic Factors by Tumor-Associated Macrophages in a Model of Inflammation-Induced Colon Cancer. *Frontiers in Immunology*, **2020**, 11, 607891	8.4	7
93	Why geneticists stole cancer research even though cancer is primarily a signaling disease. *Science Signaling*, **2019**, 12,	8.8	31

92	TAZ couples Hippo/Wnt signalling and insulin sensitivity through Irs1 expression. *Nature Communications*, **2019**, 10, 421	17.4	19
91	Clot activators do not expedite the time to predict massive transfusion in trauma patients analyzed with tissue plasminogen activator thrombelastography. *Surgery*, **2019**, 166, 408-415	3.6	4
90	Atlas Drugged. *Cell*, **2019**, 177, 803-805	56.2	0
89	Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output. *PLoS Biology*, **2019**, 17, e2006540	9.7	23
88	Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer. *Cancer Research*, **2019**, 79, 2669-2683	10.1	46
87	ROS and Oxidative Stress Are Elevated in Mitosis during Asynchronous Cell Cycle Progression and Are Exacerbated by Mitotic Arrest. *Cell Systems*, **2019**, 8, 163-167.e2	10.6	60
86	Acidification of Tumor at Stromal Boundaries Drives Transcriptome Alterations Associated with Aggressive Phenotypes. *Cancer Research*, **2019**, 79, 1952-1966	10.1	86
85	VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells. *Cell Systems*, **2019**, 9, 74-92.e8	10.6	14
84	Substrate-based kinase activity inference identifies MK2 as driver of colitis. *Integrative Biology (United Kingdom)*, **2019**, 11, 301-314	3.7	11
83	Comprehensive substrate specificity profiling of the human Nek kinome reveals unexpected signaling outputs. *ELife*, **2019**, 8,	8.9	19
82	MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4236-E4244	11.5	48
81	RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors. *Bioengineering and Translational Medicine*, **2018**, 3, 26-36	14.8	9
80	Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway. *Science Signaling*, **2018**, 11,	8.8	34
79	Histidine N(π)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 3202-3205	2.9	6
78	CADD-03. A VERSATILE AND MODULAR TARGETED NANOPARTICLE PLATFORM FOR DELIVERY OF COMBINATION THERAPIES TO ADULT AND PEDIATRIC CNS TUMORS. *Neuro-Oncology*, **2018**, 20, vi277-vi277	1	78
77	Hierarchical Organization Endows the Kinase Domain with Regulatory Plasticity. *Cell Systems*, **2018**, 7, 371-383.e4	10.6	12
76	Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. *Nature Communications*, **2018**, 9, 1991	17.4	147
75	Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. *Cancer Cell*, **2017**, 32, 411-426.e11	24.3	99

74	Protein Regulation in Signal Transduction. *Cold Spring Harbor Perspectives in Biology*, **2016**, 8,	10.2	56
73	Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma. *Cancer Cell*, **2016**, 29, 435-436	24.3	6
72	Criteria for biological reproducibility: what does "n" mean?. *Science Signaling*, **2015**, 8, fs7	8.8	15
71	Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. *Cancer Cell*, **2015**, 27, 489-501	24.3	114
70	A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. *Cancer Cell*, **2015**, 28, 623-637	24.3	51
69	Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. *Molecular Cell*, **2015**, 57, 95-107	17.6	164
68	Neighbor-directed histidine N (π)-alkylation: A route to imidazolium-containing phosphopeptide macrocycles. *Biopolymers*, **2015**, 104, 663-73	2.2	10
67	Kinetics and Role of Plasma Matrix Metalloproteinase-9 Expression in Acute Lung Injury and the Acute Respiratory Distress Syndrome. *Shock*, **2015**, 44, 128-36	3.4	41
66	Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. *Clinical Cancer Research*, **2015**, 21, 4410-9	12.9	40
65	A Multivariate Computational Method to Analyze High-Content RNAi Screening Data. *Journal of Biomolecular Screening*, **2015**, 20, 985-97		5
64	Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. *Cancer Cell*, **2014**, 26, 222-34	24.3	51
63	Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. *Cell*, **2014**, 158, 1094-1109	56.2	146
62	Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells. *Biopolymers* , **2014**, 102, 444-55	2.2	19
61	A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. *Science Signaling*, **2014**, 7, ra44	8.8	138
60	mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. *Science*, **2013**, 341, 1236566	33.3	311
59	A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. *Cell Reports*, **2013**, 5, 868-77	10.6	71
58	Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs. *Chemistry and Biology*, **2013**, 20, 1255-64		8
57	Structure of the Toxoplasma gondii ROP18 kinase domain reveals a second ligand binding pocket required for acute virulence. *Journal of Biological Chemistry*, **2013**, 288, 34968-80	5.4	14

56	The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. *Nature*, **2013**, 498, 246-50	50.4	214
55	Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. *Molecular Systems Biology*, **2012**, 8, 568	12.2	64
54	Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. *ACS Chemical Biology*, **2012**, 7, 805-10	4.9	59
53	Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1. *ChemBioChem*, **2012**, 13, 1291-6	3.8	35
52	Protein kinases display minimal interpositional dependence on substrate sequence: potential implications for the evolution of signalling networks. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2012**, 367, 2574-83	5.8	7
51	Chemical genetic screen for AMPK substrates uncovers a network of proteins involved in mitosis. *Molecular Cell*, **2011**, 44, 878-92	17.6	182
50	Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. *Nature Chemical Biology*, **2011**, 7, 595-601	11.7	84
49	Spatial exclusivity combined with positive and negative selection of phosphorylation motifs is the basis for context-dependent mitotic signaling. *Science Signaling*, **2011**, 4, ra42	8.8	126
48	Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response?. *Cell Cycle*, **2011**, 10, 23-7	4.7	31
47	Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3. *Journal of Biological Chemistry*, **2010**, 285, 4185-4194	5.4	30
46	DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. *Molecular Cell*, **2010**, 40, 34-49	17.6	169
45	Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. *PLoS Biology*, **2009**, 7, e1000111	9.7	142
44	Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. *Current Opinion in Cell Biology*, **2009**, 21, 245-55	9	392
43	Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. *Nature Structural and Molecular Biology*, **2009**, 16, 876-82	17.6	141
42	Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. *Nature*, **2008**, 455, 119-23	50.4	520
41	14-3-3sigma controls mitotic translation to facilitate cytokinesis. *Nature*, **2007**, 446, 329-32	50.4	181
40	p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. *Cancer Cell*, **2007**, 11, 175-89	24.3	471
39	Systematic discovery of in vivo phosphorylation networks. *Cell*, **2007**, 129, 1415-26	56.2	611

38	The NADPH oxidae and PI 3-kinase: the role of p40phox. *FASEB Journal*, **2007**, 21, A604	0.9	
37	"Bits" and pieces. *Science Signaling*, **2006**, 2006, pe28	8.8	5
36	MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. *Molecular Cell*, **2005**, 17, 37-48	17.6	344
35	Prologue: An Overview of Protein Modular Domains As Adaptors **2005**, 1-4		
34	The SH2 Domain: A Prototype for Protein Interaction Modules **2005**, 5-36		4
33	Structure, Specificity, and Mechanism of Protein Lysine Methylation by SET Domain Enzymes **2005**, 211-226		
32	The Structure and Function of the Bromodomain **2005**, 227-239		1
31	Chromo and Chromo Shadow Domains **2005**, 241-255		2
30	PDZ Domains: Intracellular Mediators of Carboxy-Terminal Protein Recognition and Scaffolding **2005**, 257-278		1
29	EH Domains and Their Ligands **2005**, 279-290		
28	Ubiquitin Binding Modules: The Ubiquitin Network beyond the Proteasome **2005**, 291-319		
27	The Calponin Homology (CH) Domain **2005**, 321-336		
26	PH Domains **2005**, 337-363		2
25	ENTH and VHS Domains **2005**, 365-387		
24	PX Domains **2005**, 389-408		2
23	SH3 Domains **2005**, 37-58		5
22	Peptide and Protein Repertoires for Global Analysis of Modules **2005**, 409-438		
21	Computational Analysis of Modular Protein Architectures **2005**, 439-476		2

20	Nomenclature for Protein Modules and Their Cognate Motifs **2005**, 477-486		1
19	The WW Domain **2005**, 59-72		6
18	EVH1/WH1 Domains **2005**, 73-101		1
17	The GYF Domain **2005**, 103-116		
16	PTB Domains **2005**, 117-141		
15	The FHA Domain **2005**, 143-162		
14	The Eukaryotic Protein Kinase Domain **2005**, 181-209		2
13	Epilogue: New Levels of Complexity in the Functional Roles of Modular Protein Interaction Domains: Switches and Sockets in the Circuit Diagrams of Cellular Systems Biology **2005**, 487-491		
12	The use of in vitro peptide-library screens in the analysis of phosphoserine/threonine-binding domain structure and function. *Annual Review of Biophysics and Biomolecular Structure*, **2004**, 33, 225-44		71
11	The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. *Cell*, **2003**, 115, 83-95	56.2	607
10	Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. *Nucleic Acids Research*, **2003**, 31, 3635-41	20.1	1285
9	Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. *Science*, **2003**, 299, 1228-31	33.3	577
8	Phosphotyrosine-binding domains in signal transduction. *Nature Reviews Molecular Cell Biology*, **2002**, 3, 177-86	48.7	287
7	A motif-based profile scanning approach for genome-wide prediction of signaling pathways. *Nature Biotechnology*, **2001**, 19, 348-53	44.5	479
6	The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. *Nature Cell Biology*, **2001**, 3, 675-8	23.4	516
5	Phosphoserine/threonine-binding domains. *Current Opinion in Cell Biology*, **2001**, 13, 131-8	9	302
4	MAP kinase pathways activated by stress: the p38 MAPK pathway. *Critical Care Medicine*, **2000**, 28, N67-77	7.4	260
3	14-3-3 proteins in cancer293-304		

2	Transite: A computational motif-based analysis platform that identifies RNA-binding proteins modulating changes in gene expression	1
1	Multi-Pathway DNA Double-Strand Break Repair Reporters Reveal Extensive Cross-Talk Between End-Joining, Single Strand Annealing, and Homologous Recombination	1